Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myelodisplasias

A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification

Leukemia volume 21, pages 668–677 (2007)Cite this article

Abstract

Multilineage dysplasia was advanced by the World Health Organization to increase prognostic accuracy in myelodysplastic syndromes (MDS) classification. We performed a structured cytomorphological examination of bone marrow (BM) in 221 low-grade MDS patients, this in conjunction with strict guidelines for cytopenias. A dysplasia scoring system was developed utilizing dysplastic changes, which were associated with worse outcome on univariate and multivariate analysis corrected for the International Prognostic Scoring System (IPSS). Dysplasia ⩾10% in one BM lineage and one cytopenia constituted the low-risk category UCUD or Unilineage Cytopenia and Unilineage Dysplasia. The high-risk category comprised patients with cytopenia in ⩾2 lineages and dysplasia in ⩾2 BM lineages, namely MCMD or Multilineage Cytopenia and Multilineage Dysplasia. Intermediate-risk patients had one cytopenia and multilineage dysplasia, or cytopenia in ⩾2 lineages and unilineage BM dysplasia, designated UCMD/MCUD or Unilineage Cytopenia and Multilineage Dysplasia/Multilineage Cytopenia and Unilineage Dysplasia. This system utilizing cytopenia–dysplasia scoring at diagnosis enabled comprehensive categorization of low-grade MDS cases that predicted for overall as well as leukemia-free survival. Cytopenia–dysplasia categorization added additional prognostic values to the lower risk IPSS categories. This suggests that a standardized dysplasia scoring system, used in conjunction with cytopenia, could improve diagnostic and prognostic sub-categorization of MDS patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Lichtman MA . Language and the clonal myeloid diseases. Blood 2002; 99: 725–726.

    Article  CAS  Google Scholar 

  2. Bennett JM, Catovsky D, Daniel MT . Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199.

    Article  CAS  Google Scholar 

  3. Bartl R, Frisch B, Baumgart R . Morphologic classification of the myelodysplastic syndromes (MDS): combined utilization of bone marrow aspirates and trephine biopsies. Leuk Res 1992; 16: 15–33.

    Article  CAS  Google Scholar 

  4. Garand R, Gardais J, Bizet M, Bremond JL, Accard F, Callat MP et al. Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA). Leuk Res 1992; 16: 463–468.

    Article  CAS  Google Scholar 

  5. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

    CAS  Google Scholar 

  6. Verburgh E, Achten R, Maes B, Hagemeijer A, Boogaerts M, De Wolf-Peeters C et al. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. J Clin Oncol 2003; 21: 273–282.

    Article  CAS  Google Scholar 

  7. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849.

    Article  CAS  Google Scholar 

  8. Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302.

    Article  CAS  Google Scholar 

  9. Germing U, Gattermann N, Aivado M, Hildebrandt B, Aul C . Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br J Haematol 2000; 108: 724–728.

    Article  CAS  Google Scholar 

  10. Rosati S, Mick R, Xu F, Stonys E, Le Beau MM, Larson R et al. Refractory cytopenia with multilineage dysplasia: further characterization of an ‘unclassifiable’ myelodysplastic syndrome. Leukemia 1996; 10: 20–26.

    CAS  Google Scholar 

  11. Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic Factors and life expectancy in Myelodysplastic Syndromes classified according to the WHO criteria: A basis for clinical decision making. J Clin Oncol 2005; 23: 7594–7603.

    Article  Google Scholar 

  12. Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005; 106: 2633–2640.

    Article  CAS  Google Scholar 

  13. Matsuda A, Jinnai I, Yagasaki F, Kusomoto S, Murohashi I, Bessho M et al. Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia 1998; 12: 482–485.

    Article  CAS  Google Scholar 

  14. Tassin F, Dewe W, Schaaf N, Herens C, Ravoet C, Albert A et al. A four-parameter index of marrow dysplasia has predictive value for survival in myelodysplastic syndromes. Leuk Lymphoma 2000; 36: 485–496.

    Article  CAS  Google Scholar 

  15. Beutler E, Waalen J . The definition of anemia: What is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107: 1747–1750.

    Article  CAS  Google Scholar 

  16. Maes B, Meeus P, Michaux L, Bijnens L, Boogaerts M, Hagemeijer A et al. Application of the International Prognostic Scoring System for myelodysplastic syndromes. Ann Oncol 1999; 10: 825–829.

    Article  CAS  Google Scholar 

  17. Hast R, Nilsson I, Widell S, Ost A . Diagnostic significance of dysplastic features of peripheral blood polymorphs in myelodysplastic syndromes. Leuk Res 1989; 13: 173–178.

    Article  CAS  Google Scholar 

  18. Greenberg P, Anderson J, de Witte T, Estey E, Fenaux P, Gupta P et al. Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol 2000; 18: 3447–3452.

    Article  CAS  Google Scholar 

  19. Nosslinger T, Reisner R, Koller E, Grüner H, Tüchler H, Nowotny H et al. Myelodysplastic syndromes, from French–American–British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 2001; 98: 2935–2941.

    Article  CAS  Google Scholar 

  20. Lee JH, Lee JH, Shin YR, Lee JS, Kim WK, Chi HS et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 2003; 17: 305–313.

    Article  Google Scholar 

  21. Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E . The WHO classification of MDS does make a difference. Blood 2004; 103: 3265–3270.

    Article  CAS  Google Scholar 

  22. Germing U, Gattermann N, Strupp C, Aivado M, Aul C . Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000; 24: 983–992.

    Article  CAS  Google Scholar 

  23. Sanz GF, Sanz MA, Vallespi T, del Canizo MC . Two types of acquired idiopathic sideroblastic anaemia. Br J Haematol 1990; 75: 633–634.

    Article  CAS  Google Scholar 

  24. Sanz GF, Sanz MA, Vallespi T, del Canizo MC . Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395–408.

    CAS  Google Scholar 

  25. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D . Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59: 425–433.

    Article  CAS  Google Scholar 

  26. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993; 7: 1315–1323.

    CAS  Google Scholar 

  27. Bennett JM, Brunning RD, Vardiman JW . Myelodysplastic syndromes: from French–American–British to World Health Organization: a commentary. Blood 2002; 99: 3074–3075.

    Article  CAS  Google Scholar 

  28. Steensma DP, Tefferi A . The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 2003; 27: 95–120.

    Article  Google Scholar 

  29. Tamura S, Takemoto Y, Wada H, Itoh T, Mori A, Saheki K et al. Significance of trilineage myelodysplasia in de novo acute myeloid leukaemia during remission rather than at diagnosis. Br J Haematol 1998; 101: 743–748.

    Article  CAS  Google Scholar 

  30. Miyazaki Y, Kuriyama K, Miyawaki S, Ohtake S, Sakamaki H, Matsuo T et al. Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study. Br J Haematol 2003; 120: 56–62.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, University of Leuven, Leuven, Belgium

    E Verburgh, V J Louw, C Brusselmans, M Delforge, M Boogaerts & G Verhoef

  2. Department of Morphology and Molecular Pathology, University of Leuven, Leuven, Belgium

    R Achten

  3. The Center for Human Genetics, University of Leuven, Leuven, Belgium

    A Hagemeijer & P Vandenberghe

Authors
  1. E Verburgh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Achten
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V J Louw
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Brusselmans
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Delforge
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Boogaerts
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Hagemeijer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P Vandenberghe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Verhoef
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Verburgh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Verburgh, E., Achten, R., Louw, V. et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia 21, 668–677 (2007). https://doi.org/10.1038/sj.leu.2404564

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404564

Keywords

This article is cited by

Search

Advanced search

Quick links